About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Melanoma Clinical Trials in Pittsburgh | 248 Studies

Clinical Trials MelanomaPittsburgh

Melanoma Clinical Trials in Pittsburgh

Find 248 clinical trials for melanoma near Pittsburgh, Pennsylvania. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Pittsburgh

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 141-160 of 248 trials

CompletedPixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)The primary goal of this trial is to assess clinical response to nivolumab and pixatimod, and, nivolumab, pixatimod and cyclophosphamide in three separate patient cohorts.NCT05061017·Pittsburgh, Pennsylvania Active not recruitingTTX-080 HLA-G Antagonist in Subjects With Advanced CancersTTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy…NCT04485013·Tucson, Arizona and 40 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedCombination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic MelanomaThe combination of TMZ and DAC may effect dual modulation of DNA repair genes resulting in improved clinical response.NCT00715793·Pittsburgh, Pennsylvania

CompletedAnti-Angiogenesis Agent AG-013736 In Patients With Metastatic MelanomaThis is a Phase 2 study being conducted at multiple centers in the United States and France.NCT00094107·Orange, California and 11 others

RecruitingA Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called…NCT06246916·Chandler, Arizona and 111 others

CompletedPhase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic MelanomaThis was a Phase 2, open-label study of KW2871 (ecromeximab) in combination with high-dose interferon-α2b (HDI) in patients with metastatic melanoma.NCT00679289·Chicago, Illinois and 1 other

Active not recruitingA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersThe purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to…NCT05544929·Boston, Massachusetts and 18 others

CompletedA Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic MelanomaThe purpose of this study is to determine the safety profile, pharmacokinetics, pharmacodynamics and maximum tolerated dose of RAF265 in patients with locally advanced and…NCT00304525·Aurora, Colorado and 10 others

TerminatedLive Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid TumorsThis is an open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell…NCT03637803·Kansas City, Kansas and 4 others

RecruitingA Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or…NCT06022029·Los Angeles, California and 15 others

RecruitingEvolution of Metabolic and Immune Dysfunction in In-transit MelanomaMelanoma in-transit metastases (ITMs) continue to represent a therapeutic dilemma, in that no standard method of treatment has been uniformly adopted.NCT04658303·Pittsburgh, Pennsylvania

TerminatedTrial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant MelanomaThis phase 2 clinical trial randomizes patients with BRAF mutant melanoma to either (1) standard of care (SOC) - BRAF inhibitor vemurafenib in combination with MEK inhibitor…NCT01495988·Los Angeles, California and 13 others

CompletedImmunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for MelanomaIpilimumab is a manufactured monoclonal antibody, much like the antibodies usually made by the human body to fight off infection; however it is not known why the human body does…NCT00972933·Pittsburgh, Pennsylvania

TerminatedStudy of IK-595 in RAS- or RAF-altered Advanced TumorsThis is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary…NCT06270082·Duarte, California and 14 others

CompletedA Study of Intratumoral IMO-2125 in Patients With Refractory Solid TumorsThis is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.NCT03052205·Scottsdale, Arizona and 11 others

CompletedCAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumorsNCT03504488·Tucson, Arizona and 58 others

CompletedPhase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected MelanomaThis is a study of an investigational cancer vaccine called GRN-1201. Treatment with the GRN-1201 vaccine is a type of immunotherapy.NCT02696356·Cincinnati, Ohio and 3 others

CompletedSafety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerThe purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Keytruda (pembrolizumab) when given to patients with B7-H3-expressing melanoma…NCT02475213·Scottsdale, Arizona and 19 others

CompletedDasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By SurgeryRATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.NCT00700882·Little Rock, Arkansas and 152 others

Active not recruitingZimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory MelanomaThe main goal of this study is to establish the proportion of patients with objective response to zimberelimab/domvanalimab in PD-1 R/R melanoma patients.NCT05130177·Pittsburgh, Pennsylvania

PreviousPage 8 of 13Next

Other Conditions in Pittsburgh

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma